# Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

> **NCT04695197** · PHASE3 · COMPLETED · sponsor: **Liverpool School of Tropical Medicine** · enrollment: 143 (actual)

## Conditions studied

- Covid-19
- Malaria

## Interventions

- **DRUG:** Artemether-lumefantrine (AL)
- **DRUG:** Pyronaridine-artesunate (PA)

## Key facts

- **NCT ID:** NCT04695197
- **Lead sponsor:** Liverpool School of Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2022-11-01
- **Final completion:** 2024-02-20
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2024-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695197, "Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04695197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*